SurvivorNet on MSN8mon
New Hope for Ovarian Cancer: FDA Approves Targeted Drug ELAHERE for Certain Patients With Difficult-to-Manage DiseaseOvarian cancer is a serious disease ... which kills the cancer cell. This form of targeted therapy potentially saves patients ...
Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...
The Wistar Institute's Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center's Molecular and ...
GlobalData on MSN7d
Roche secures CE mark for ovarian cancer detection testRoche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...
The therapy is authorised for patients who have undergone one to three prior systemic treatment regimens. Approximately ...
Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...
A simple blood test could soon predict which ovarian cancer patients will stop responding to their treatment, paving the way ...
The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.
Vintafolide is a novel folate receptor (FR)-targeted agent that has demonstrated clinical activity and a good toxicity profile in patients with ovarian cancer and adenocarcinoma of the lung.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback